UNSPSC 51434920: Chlorothiazide/methyldopa

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434920 Chlorothiazide/methyldopa, a Commodity code, covers pharmaceutical supply contracts for state and local health systems, emergency response agencies, and multistate cooperative purchasing vehicles. Recent solicitations show state and local governments buying emergency medications (epinephrine, diltiazem, adenosine, labetalol) through sealed competitive bids, generic multi-source pharmaceuticals through cooperative purchasing frameworks, and exploring direct-to-manufacturer prescription programs to reduce costs and improve distribution efficiency. Issuing bodies include city fire and rescue departments (Tampa Fire Rescue), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving state agencies and local government facilities across participating states including Oregon). The solicitations reflect a mix of emergency supply procurement, routine generic pharmaceutical distribution, and strategic state-level initiatives to reshape pharmacy benefit delivery outside traditional pharmacy benefit manager and group purchasing organization channels.

Activity is concentrated in Texas, Minnesota, and Florida, with broader geographic reach through multistate cooperative vehicles. The City of Tampa's Purchasing Department issued IFB 26P00188 on April 24, 2026, for Advanced Life Support Medications with a due date of April 8, 2026 (noted as posted after the due date, indicating possible amendment or posting lag), seeking four specific medication line items with a $40,000 estimated value and a Small Local Business Enterprise 5 percent bid discount available. Minnesota's MMCAP, administered through the Minnesota Department of Administration's Office of State Procurement, issued an RFP for Generic Multi Source Pharmaceuticals and OTC Products with a March 26, 2026 response deadline; vendors must work through three authorized wholesalers and pay a 3 percent administrative fee, with contract terms running two years from July 1, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription capabilities—a preliminary information-gathering phase with no formal award value, intended to shape future formal solicitation strategy.